News

CRISPRMED24 Testimonial - Laura Castilla-Vallmanya, Ph.D

CRISPRMED25 is an event not to be missed, but don't take it from us! Hear what some of CRISPRMED24 attendees have to say about the conference in this new video series by WeDoCRISPR!

By: WeDoCRISPR - Jan. 21, 2025
News

Laura Castilla-Vallmanya is a postdoctoral researcher at the Molecular Neurogenetics group led by Prof. Johan Jakobsson at Lund Stem Cell Center (Sweden), where she investigates the role of transposable elements (TEs) and their regulators in neurodevelopmental disorders using advanced 2D and 3D in vitro iPSC-based cell models, CRISPR methods and next generation sequencing. In this WeDoCRISPR video, she reflects on presenting her research at the inaugural CRISPR Medicine Conference in April 2024, in which she and her colleagues described the link between TE repressor mutations and neurodevelopmental disorders. She particularly valued the conference's unique focus on academia-industry collaboration and its insights into translating CRISPR technologies from research to clinical applications, noting its relevance for scientists at all career stages.

Tags

HashtagArticleHashtagNewsHashtagWeDoCRISPRHashtagCRISPRMED24HashtagCRISPRMED25

News: CRISPRMED24 Testimonial - Laura Castilla-Vallmanya, Ph.D
CLINICAL TRIALS
Systemic Lupus Erythematosus, SLE, (NCT06752876)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Hepatitis B, HBV, (NCT06671093)
Sponsors:
Tune Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine